دورية أكاديمية
أعرض في EDS

Clinical and genome-wide association analysis of chemoradiation-induced hearing loss in nasopharyngeal carcinoma.

التفاصيل البيبلوغرافية
العنوان: Clinical and genome-wide association analysis of chemoradiation-induced hearing loss in nasopharyngeal carcinoma.
المؤلفون: He YQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China., Luo LT; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.; School of Public Health, Sun Yat-sen University, Guangzhou, People's Republic of China., Wang TM; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China., Xue WQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China., Yang DW; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.; School of Public Health, Sun Yat-sen University, Guangzhou, People's Republic of China., Li DH; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China., Diao H; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.; School of Public Health, Sun Yat-sen University, Guangzhou, People's Republic of China., Xiao RW; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China., Deng CM; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China., Zhang WL; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China., Liao Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China., Wu YX; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China., Wang QL; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.; School of Public Health, Sun Yat-sen University, Guangzhou, People's Republic of China., Zhou T; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.; Biobank of Sun Yat‑sen University Cancer Center, Guangzhou, People's Republic of China., Li XZ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.; Biobank of Sun Yat‑sen University Cancer Center, Guangzhou, People's Republic of China., Zheng XH; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.; Biobank of Sun Yat‑sen University Cancer Center, Guangzhou, People's Republic of China., Zhang PF; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.; Biobank of Sun Yat‑sen University Cancer Center, Guangzhou, People's Republic of China., Zhang SD; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.; Biobank of Sun Yat‑sen University Cancer Center, Guangzhou, People's Republic of China., Hu YZ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.; Biobank of Sun Yat‑sen University Cancer Center, Guangzhou, People's Republic of China., Sun Y; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China., Jia WH; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China. jiawh@sysucc.org.cn.; School of Public Health, Sun Yat-sen University, Guangzhou, People's Republic of China. jiawh@sysucc.org.cn.; Biobank of Sun Yat‑sen University Cancer Center, Guangzhou, People's Republic of China. jiawh@sysucc.org.cn.
المصدر: Human genetics [Hum Genet] 2023 Jun; Vol. 142 (6), pp. 759-772. Date of Electronic Publication: 2023 Apr 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7613873 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1203 (Electronic) Linking ISSN: 03406717 NLM ISO Abbreviation: Hum Genet Subsets: MEDLINE
أسماء مطبوعة: Publication: Berlin : Springer Verlag
Original Publication: Berlin, New York, Springer-Verlag.
مواضيع طبية MeSH: Hearing Loss*/chemically induced , Hearing Loss*/genetics , Deafness* , Nasopharyngeal Neoplasms*/genetics , Nasopharyngeal Neoplasms*/therapy , Nasopharyngeal Neoplasms*/chemically induced, Humans ; Nasopharyngeal Carcinoma/genetics ; Cisplatin/adverse effects ; Genome-Wide Association Study ; Quality of Life
مستخلص: Chemoradiation-induced hearing loss (CRIHL) is one of the most devasting side effects for nasopharyngeal carcinoma (NPC) patients, which seriously affects survivors' long-term quality of life. However, few studies have comprehensively characterized the risk factors for CRIHL. In this study, we found that age at diagnosis, tumor stage, and concurrent cisplatin dose were positively associated with chemoradiation-induced hearing loss. We performed a genome-wide association study (GWAS) in 777 NPC patients and identified rs1050851 (within the exon 2 of NFKBIA), a variant with a high deleteriousness score, to be significantly associated with hearing loss risk (HR = 5.46, 95% CI 2.93-10.18, P = 9.51 × 10 -08 ). The risk genotype of rs1050851 was associated with higher NFKBIA expression, which was correlated with lower cellular tolerance to cisplatin. According to permutation-based enrichment analysis, the variants mapping to 149 hereditary deafness genes were significantly enriched among GWAS top signals, which indicated the genetic similarity between hereditary deafness and CRIHL. Pathway analysis suggested that synaptic signaling was involved in the development of CRIHL. Additionally, the risk score integrating genetic and clinical factors can predict the risk of hearing loss with a relatively good performance in the test set. Collectively, this study shed new light on the etiology of chemoradiation-induced hearing loss, which facilitates high-risk individuals' identification for personalized prevention and treatment.
(© 2023. The Author(s).)
References: Lancet. 2019 Jul 6;394(10192):64-80. (PMID: 31178151)
JAMA Otolaryngol Head Neck Surg. 2015 Sep;141(9):810-5. (PMID: 26291150)
Cancer. 2006 Feb 15;106(4):820-9. (PMID: 16421885)
Cancer. 2021 Nov 01;127(21):4091-4102. (PMID: 34286861)
Hear Res. 2014 Jun;312:60-8. (PMID: 24650954)
Nat Genet. 2006 Jul;38(7):770-8. (PMID: 16804542)
Am J Hum Genet. 2008 Aug;83(2):278-92. (PMID: 18674745)
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S50-7. (PMID: 20171518)
Nature. 2012 Mar 28;483(7391):603-7. (PMID: 22460905)
Clin Cancer Res. 2019 Jul 1;25(13):4104-4116. (PMID: 30952644)
N Engl J Med. 2019 Sep 19;381(12):1124-1135. (PMID: 31150573)
Cancer Res. 2019 Dec 15;79(24):6227-6237. (PMID: 31558563)
Transl Oncol. 2015 Dec;8(6):456-62. (PMID: 26692526)
Development. 2010 Nov;137(22):3835-45. (PMID: 20978075)
Bioinformatics. 2019 Jun 1;35(11):1968-1970. (PMID: 30395168)
Ann Intern Med. 2011 Mar 1;154(5):347-55. (PMID: 21357912)
Trends Neurosci. 1997 Jun;20(6):252-8. (PMID: 9185306)
J Assoc Res Otolaryngol. 2008 Sep;9(3):290-306. (PMID: 18584244)
OMICS. 2012 May;16(5):284-7. (PMID: 22455463)
J Assoc Res Otolaryngol. 2007 Sep;8(3):338-55. (PMID: 17516123)
Genet Mol Res. 2007 Dec 11;6(4):1131-41. (PMID: 18273807)
Nat Genet. 2015 Mar;47(3):263-6. (PMID: 25665007)
Biomed Res Int. 2021 Dec 21;2021:3548706. (PMID: 34970625)
NPJ Precis Oncol. 2021 Jul 14;5(1):64. (PMID: 34262104)
Hum Mol Genet. 2011 Aug 15;20(16):3213-26. (PMID: 21610158)
Bioinformatics. 2016 Apr 15;32(8):1244-6. (PMID: 26656004)
Genes (Basel). 2021 Mar 26;12(4):. (PMID: 33810548)
J Natl Cancer Inst. 2019 Jun 1;111(6):620-628. (PMID: 30299488)
Annu Rev Immunol. 2009;27:693-733. (PMID: 19302050)
Int J Pediatr Otorhinolaryngol. 2020 Jun;133:109947. (PMID: 32087478)
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1393-402. (PMID: 15817342)
PLoS Genet. 2015 Mar 25;11(3):e1005097. (PMID: 25807530)
Radiother Oncol. 2021 Apr;157:99-105. (PMID: 33484752)
Nat Commun. 2016 Apr 25;7:11428. (PMID: 27109210)
Radiother Oncol. 2014 Jul;112(1):106-11. (PMID: 24933452)
Chin J Cancer. 2017 Mar 6;36(1):26. (PMID: 28264724)
Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1335-42. (PMID: 18922648)
Cancer. 2016 Jun 1;122(11):1647-58. (PMID: 26859792)
Nat Commun. 2022 Apr 12;13(1):1966. (PMID: 35414057)
Am J Transplant. 2017 Jan;17(1):201-209. (PMID: 27272414)
J Neurosci. 2006 Mar 29;26(13):3541-50. (PMID: 16571762)
Brain. 1996 Jun;119 ( Pt 3):741-53. (PMID: 8673487)
Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61. (PMID: 23180760)
Clin Cancer Res. 2019 Feb 15;25(4):1147-1155. (PMID: 30305294)
Clin Cancer Res. 2017 Jul 1;23(13):3325-3333. (PMID: 28039263)
Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13396-401. (PMID: 20624953)
Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):281-9. (PMID: 8892450)
Am J Hum Genet. 2019 Oct 3;105(4):788-802. (PMID: 31564434)
PLoS Genet. 2016 Oct 20;12(10):e1006371. (PMID: 27764096)
Cancers (Basel). 2020 May 17;12(5):. (PMID: 32429551)
Hear Res. 2019 Aug;379:59-68. (PMID: 31096078)
Lancet Oncol. 2018 Apr;19(4):461-473. (PMID: 29501366)
Nat Genet. 2006 Aug;38(8):904-9. (PMID: 16862161)
J Natl Compr Canc Netw. 2020 Jul;18(7):873-898. (PMID: 32634781)
Proc Natl Acad Sci U S A. 2016 May 24;113(21):5993-8. (PMID: 27162350)
J Clin Oncol. 2006 Apr 20;24(12):1904-9. (PMID: 16622266)
Cell Res. 2011 Jan;21(1):86-102. (PMID: 21102550)
Hum Mol Genet. 2002 Nov 1;11(23):2877-85. (PMID: 12393799)
Am J Med Genet A. 2013 Aug;161A(8):2060-5. (PMID: 23813623)
J Neurosci Res. 2005 Mar 1;79(5):644-51. (PMID: 15672440)
معلومات مُعتمدة: 2021YFC2500400 National Key Research and Development Program of China; 2021B1515420007 Basic and Applied Basic Research Foundation of Guangdong Province, China; 2014TX01R201 Special Support Program for High-level Professionals on Scientific and Technological Innovation of Guangdong Province, China; 81903395 National Natural Science Foundation of China; 82003520 National Natural Science Foundation of China; 2019B110233004 Key Area Research and Development Program of Guangdong Province, China
المشرفين على المادة: Q20Q21Q62J (Cisplatin)
تواريخ الأحداث: Date Created: 20230416 Date Completed: 20230515 Latest Revision: 20230515
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10182145
DOI: 10.1007/s00439-023-02554-0
PMID: 37062025
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-1203
DOI:10.1007/s00439-023-02554-0